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Introduction
The search for new synthetic bone grafts is a topic of exten-
sive research. Although autografts are the gold standard for 
targeted bone regeneration, they present some disadvan-
tages such as pain morbidity, disease transmission, and lim-
ited availability.1–7 The development of synthetic materials 
is an alternative strategy to overcome the limitations asso-
ciated with these problems. The challenge to material sci-
entists is to produce biomaterials with properties that mimic 
the natural extracellular matrix of bone tissue, which is 
mainly composed of hydroxyapatite (HA) and collagen.8 
Hence comes the potential for calcium phosphate-based 
materials, which resemble the bone mineral phase, and 
more specifically calcium phosphate cements (CPCs). This 
family of materials allows self-setting HA or brushite 
(dicalcium phosphate dihydrate (DCPD)) to be obtained by 
soft chemistry routes. The properties of these two families 
of cements are quite different. HA CPCs tend to be stronger. 
Moreover, since DCPD is metastable in physiological con-
ditions, brushite CPCs are much faster resorbable than apa-
tite CPCs, although it has been shown that in vivo DCPD 
tends to convert into precipitated hydroxylapatite (PHA). 
CPCs are composed of a powder phase and a liquid phase, 
which are mixed to form a moldable and injectable paste at 
a determined liquid to powder (L/P) ratio to obtain a final 
product different from the initial reagents. The final 
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properties of this end product can be tailored by changing 
different processing parameters, such as the composition 
and granulometry of the powder phase, the composition of 
the liquid phase, or L/P used. The final CPC product arises 
from a dissolution–precipitation reaction, which produces 
hydrated compounds with a composition and morphology 
close to the calcium phosphates found in mineralized 
tissues.9
An approach that is attracting much attention in the CPC 
field is to incorporate polymers into the formulation, either 
as a second solid phase or dissolved in the liquid phase. 
This appears to be an excellent option to enhance CPC per-
formance and improve not only some properties relevant 
for the clinical use of these materials, such as injectability, 
cohesion, or setting time, but also their final performance in 
terms of resorption rate and cell/tissue response.
The scope of this study is to overview the role of poly-
mers in the design of more efficient CPC formulations. The 
use of different natural and synthetic polymers is reviewed, 
and their effects on different CPC properties are analyzed.
Why add a polymer to a CPC?
Incorporating polymers has been a strategy to overcome the 
intrinsic limitations of an inorganic CPC. Many properties 
can be improved by adding a polymer phase. Although the 
effect of adding a polymer depends on the composition of 
the organic phase, the main trends for some relevant CPC 
properties are summarized in the following.
Setting time
The setting time is the time when the CPC paste loses its 
plasticity and starts to harden to form a solid body. Setting 
times are usually measured by indentation, which is a fast 
and easy system, although it is imprecise. The most com-
monly used method consists of two Gilmore needles with 
different loads that may penetrate into the sample depend-
ing on the hardness of the solid paste. Once the needles do 
not penetrate the sample, the setting time is completed. A 
CPC must have appropriate setting times of 5–15 min.10 As 
a general rule, the presence of polymers tends to increase 
setting time, which may be related to the higher viscosity of 
the polymer-containing paste, which hinders ion diffusion 
in the matrix.
Cohesion/washout resistance
Cohesion is the ability of a paste to set in a fluid without 
disintegrating. Different terms have been used to describe 
this property, such as nondecay ability, antiwashout, com-
pliance, swelling, or stability, and several studies have been 
performed on this topic.10–16 Nevertheless, disintegration of 
the cement paste, in addition to preventing the cement from 
setting, can provoke an inflammatory response and cell 
apoptosis.17 For this reason, the cohesion time should be 
lower than the initial setting time to guarantee the structural 
integrity of the cement paste.10 In general, adding soluble 
polymers during the liquid phase tends to enhance CPC 
cohesion. The mechanism underlying this phenomenon is 
the increased viscosity of the CPC paste, which prevents 
penetration of the surrounding fluid.
Injectability
Injectability is a CPC property most appreciated by clini-
cians, as it allows minimizing the surgery and permits ade-
quate filling of complex-shaped defects. Injectability is the 
ability of a paste to be extruded through a needle without 
demixing. Injectability can be increased by increasing the 
CPC L/P ratio, although this adversely affects mechanical 
properties.18,19 Some water-soluble polymers, such as poly-
saccharides, have been extensively used to enhance CPC 
injectability and to increase cohesion time.
Macroporosity
CPCs are intrinsically porous materials, with pores in the 
micro- or nanometer range,20 but lack macroporosity, which 
is an essential feature for tissue colonization and angiogen-
esis. Two main routes have been explored to introduce 
macroporosity into CPCs by adding polymers: (a) foaming 
the liquid phase or the cement paste containing a poly-
mer,21–25 and (b) loading the CPC with biodegradable poly-
mers (e.g. microspheres (MSs) or fibers) that slowly 
degrade over time, resulting in a macroporous structure.26,27 
Actually, even a third method has been proposed in which a 
collagen and CPC slurry are freeze–dried to produce   
a macroporous scaffold, although this is no longer 
injectable.28
Mechanical properties
Poor mechanical performance of CPCs has limited their 
applicability to nonload-bearing applications.29 Due to the 
intrinsic porosity of CPCs, their strength is lower than that 
of calcium phosphate ceramics. Moreover, their toughness, 
ductility, and fatigue resistance are much less than those of 
cortical bone. Incorporating a polymer during the CPC liq-
uid phase increases ductility, allowing for a higher deforma-
tion before breaking. Moreover, polymer fiber reinforcement 
has been extensively explored as a strategy to increase 
toughness and strength of cements.30
Long-term degradation
One of the main drawbacks when working with most 
CPCs, particularly those resulting in HA as the reaction 
product, is their slow resorption rate, which impairs heal-
ing. In this sense, the strategies mentioned previously Perez et al.  3
aimed at creating macropores in the CPC, namely, incor-
poration of biodegradable polymers and foaming, also 
result in an increase in the degradation rate.
Drug eluting properties
The intrinsic porosity of CPCs has been exploited for use in 
drug delivery applications. The combination of CPC with 
polymers has been used as a way to tune drug release 
kinetics.
Biological response
CPCs generally have low cell attachment and low prolifera-
tion rates when cells are cultured in vitro, basically due to 
the spiky crystal morphology that arises from the precipita-
tion of the initial powder.31–36 Therefore, incorporating 
some polymers may add specific binding domains to permit 
cell adhesion. The most well-known specific binding 
domains are those related to cell attachment, such as the 
RGD sequence found in gelatin.
The different properties that can be enhanced by the 
addition of the specific polymers in the CPC are listed in 
Table 1.
Ways of incorporating polymers  
to CPCs
CPCs are composed of a powder phase and a liquid phase. 
Therefore, polymers can be added to CPC, either dissolved 
in the liquid phase or in a solid state as an additive to the 
powder phase, as shown schematically in Figure 1. 
Obviously, only water-soluble polymers can be added to 
the CPC liquid phase. In this case, the polymer will be pre-
sent as a continuous phase throughout the entire CPC and, 
what is more important, the solubilized polymer will be 
able to interact with the cement setting reaction, namely the 
dissolution of the original phase and the precipitation of the 
final product. Depending on the final CPC properties 
desired, the liquid phase properties may be altered by 
changing several features of the polymer, such as concen-
tration, molecular weight, and polymer chain length. 
Conversely, when the polymers are added in solid form, 
they will act as a second and discontinuous phase in the 
cement inorganic matrix. Although the extent of chemical 
interaction with the setting reaction is expected to be lower, 
the morphology, size, and percentage of this second phase 
will have significant effects on the handling properties and 
on the final performance of the material.
Table 1.  Some properties of calcium phosphate cements that can be improved by the incorporation of a polymeric phase and the 
corresponding polymers
Property improved Polymers associated in liquid phase Polymers associated in powder phase
Setting time Alginate —
  Chitin  
  PEG  
Cohesion Chitosan —
  Alginate  
  Silk  
  PEG  
Injectability Hyaluronate —
  Cellulose  
Macroporosity Soybean Gelatin
  Albumen Polyesters
Mechanical properties Gelatin Chitosan
  Chitosan Polyesters
  Chitin  
  Polyesters  
  PAA  
  Fibrin glue  
Long-term degradation — Gelatin
  Chitosan
  Polyesters
Drug eluting system Chitosan Gelatin
  Polyesters Polyesters
  PAA  
Biological response Gelatin Alginate
  Collagen Polyesters
PEG: polyethylene glycol; PAA: polyacrylic acid.4  Journal of Tissue Engineering 3(1)
Polymers incorporated into 
CPCs and their effects on CPCs 
properties
This section describes the most significant advances in the 
development of polymer-modified CPC. The results are 
classified according to the way of adding the polymer 
within the CPC, and in function of the origin of the poly-
mer, namely, natural or synthetic. Further details of the dif-
ferent formulations are summarized in Table 2.
Polymer addition in the liquid phase
Natural polymers
Gelatin.  Gelatin is a natural polymer derived from col-
lagen, being in fact denatured collagen. Gelatin is soluble 
in water and shows increased solubility as temperature 
increases. Gelatin gels at temperatures <38°C–40°C.126 
The triple helical structure of collagen is degraded, and 
uncoiled structures are formed during gelatin processing. 
This results in exposing the RGD sequence found in the 
triple helical structure of collagen, which is a specific bind-
ing amino acid sequence for cells to attach. Therefore, one 
of the main reasons to incorporate gelatin into a CPC is to 
enhance cell adhesion. Some studies have shown a posi-
tive effect of incorporating gelatin on initial cell adhesion 
and proliferation,37,127 although other studies have reported 
only a small effect on cell proliferation.38,39 Moreover, an 
increase in the production of bone-related proteins after 
3 and 7 days of culture, indicating an increase in osteo-
blastic activity and differentiation, is observed in gelatin-
containing CPCs.39 The same authors showed that gelatin 
stimulated alkaline phosphatase (ALP) activity as well as 
collagen and transforming growth factor 31 production.127 
Data indicate that gelatin in CPCs favors osteoblast pro-
liferation and activates their metabolism and differentia-
tion.127
Nevertheless, gelatin may negatively affect other param-
eters, such as setting time, which increases due to the 
increase in paste viscosity, and subsequent ion diffusion 
difficulties. Gelatin increases the setting time for a CPC 
composed of monocalcium phosphate monohydrate 
(MCPM)-CaCO3; this increase is more pronounced as gela-
tin concentration is increased.38,40 The same effect is found 
for a CPC composed of amorphous calcium phosphate 
(ACP)–DCPD.41 In contrast, the time to completely trans-
form α-tricalcium phosphate (TCP) into calcium-deficient 
HA was advanced from 7 days in the control CPC to 2 days 
for the gelatin containing TCP.42
Gelatin also affects CPC mechanical properties, although 
in different ways depending on the amount of gelatin incor-
porated. Gelatin increases the compressive strength of an 
α-TCP cement fourfold, which is related to a decrease in 
sample porosity.43 Compressive strength increases linearly 
as a function of gelatin concentration.42 Nevertheless, the 
general trend is that the highest strengths are obtained with 
low gelatin concentrations rather than with high gelatin 
Figure 1.  Different strategies for incorporating polymers in CPCs. The polymer can be incorporated either in the liquid phases (A, 
B, and C) or in the powder phases (D and E). A represents the mixing of a polymeric solution with the CPC powder to obtain a set 
CPC, which has the polymer homogeneously distributed in the structure. B represents foaming of the liquid solution, which is then 
combined with the powder to obtain a set macroporous CPC. C represents the incorporation of a small amount of CPC powder in 
a big volume of polymer solution, upon which a slurry is formed and is then freeze–dried, resulting in a macroporous polymer–CPC 
scaffold. D represents the combination of the powder phase with polymer fibers to obtain a fiber-reinforced CPC. Moreover, the 
fibers may act as pore generators when degraded. E represents the combination of the powder phase with polymer MSs, which can 
act as controlled drug eluting systems and simultaneously generate macropores in the CPC.
CPC: calcium phosphate cement.Perez et al.  5
Table 2.  Description of the different natural and synthetic polymers incorporated into the liquid or the powder phase of the CPC 
Polymer name % Weight/
specifications
Liquid  
phase
CPC  
composition
CPC  
end product
L/P  
ratio
Main effect References
Liquid phase
  Natural polymers
 Gelatin 0%–20% H2O or 
Na2HPO4 
solution
α-TCP HA 0.40–0.80 Foaming of the gelatin 
solution results in 
injectable self-setting 
gelatin–HA foams
23, 25
  5% 10× PBS α-TCP HA 1.2 Increase in initial 
cell adhesion and 
proliferation
37
  0%–10% H2O CaCO3–MCPM HA 0.55 Increase in setting 
time. Small effect 
on cell proliferation. 
Decrease in mechanical 
properties
38
  15% H2O α-TCP–DCPD HA 0.3 Similar proliferation 
values, but enhanced 
primary osteoblast 
activation and ECM 
mineralization process
39
  2%–10% H2O CaCO3–MCPM HA 0.4 Increase in setting time. 
Higher mechanical 
properties for lowest 
gelatin concentration 
(2%)
40
  20% H2O ACP–DCPD HA — Increase in setting time. 
Decrease in mechanical 
properties
41
  0%–20% H2O α-TCP–DCPD HA 0.3 Faster final production. 
Increase in mechanical 
properties with 
increase in gelatin 
concentration
42
  10% H2O α-TCP–DCPD HA 0.3–0.4 Increase in 
compressive strength
43
  0%–20% H2O α-TCP HA 0.28–0.5 Increased mechanical 
properties when 
gelatin concentration 
up to 5%
44
 Collagen 0%–5%;  
fibers  
(∅ = 0.1–3 µm;  
L = 20–100 µm)
H2O TTCP–DCPA HA 0.25–0.4 Increase in cell 
adhesion. Decrease in 
compressive strength 
as collagen percentage 
was increased
45
  3% 100–800 mM 
citric acid
MCPM–β-TCP DCPD 0.29 Increase in cell 
adhesion. Mechanical 
properties maintained 
similar to control
46
  0%–2% H2O/0.2 M 
N2HPO4
TTCP–DCPA HA 0.29 Increase in setting 
times. Decrease in 
compressive strength 
as collagen percentage 
was increased
47
 Chitosan 20% H2O ACP–DCPD HA 0.2 Increase in setting 
times. Decrease in 
compressive strength
41
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Polymer name % Weight/
specifications
Liquid  
phase
CPC  
composition
CPC  
end product
L/P  
ratio
Main effect References
  0%–20% H2O TTCP–DCPA HA 0.5 Increase in setting time. 
Increase in flexural 
strength
48
  40% Glycerol and 
Ca(OH)2
TTCP–DCPA HA 0.5 Increase in setting time. 
Increased antiwashout 
properties. Increase 
in diametral tensile 
strength. No cell 
cytotoxicity
49
  0%–6% 1 M phosphate 
buffer
MCPM–CaO HA 0.44–1.04 Increase in 
compressive strength 
for low chitosan 
percentage. Decrease 
in compressive 
strength higher than 
3%
50
  0%–15% 1 M Na2HPO4 DCPD–
Ca(OH)2
HA 0.44–1.04 Increase in setting 
times. Increase in 
compressive strength 
as chitosan percentage 
is increased
50
  0%–8% 0.15 g MgCO3 
+ 0.18 mL 30 
wt.% H3PO4
α-TCP or TTCP HA 0.125 Conversion to HA 
inhibited by large 
amounts of chitosan
51
  0%–30% H2O TTCP–DCPA HA 0.5 Reduction in setting 
times. Increase in 
flexural strength up to 
20 wt.% chitosan
52
  0%–15% H2O TTCP–DCPA HA 0.22–0.5 Increase in flexural 
strength. No significant 
effect on cell activity
53–58
  0%–15% H2O TTCP–DCPA HA 0.5 Increase in flexural 
strength. Significant 
increase in ALP cell 
activity
59, 60
  0%–15% H2O TTCP–DCPA HA 0.5 Increase in flexural 
strength
61
  2% 1.5% Acetic acid 
solution
α-TCP HA 0.33 Increase in 
compressive strength. 
No cell cytotoxicity. 
Bigger osteoclastic cell 
morphology
62
  0%–15% 5% Malic and 
malonic acid
β-TCP, CaO, 
MgO, ZnO. 
TTCP–DCPA
HA 0.7 Increase antiwashout 
properties. No 
significant effect on 
injectability
63–67
  0%–12% 1 M Na2HPO4 MCPM–CaO 
or DCPD–
Ca(OH)2
HA 0.96 or 
2.29
Negative effect 
of chitosan on 
biodegradation
68
  0%–15% PBS with 0–100 
ng/mL protein A 
solutions
TTCP–DCPA HA 0.25–0.5 Sustained release of 
gentamicin
69
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Polymer name % Weight/
specifications
Liquid  
phase
CPC  
composition
CPC  
end product
L/P  
ratio
Main effect References
 Alginate 2.2% 0.2 M neutral 
phosphate 
solution
TTCP–DCPA HA 0.29 Increase in setting 
time. No significant 
effect of alginate 
on compressive 
strength up to 10% 
concentration
70
  2% 0.2 M neutral 
phosphate 
solution
TTCP–DCPA HA 0.25 No effect on setting 
time. Decrease in 
tensile diametral 
strength
12
  0%–0.5% 1 M Na2HPO4 MCPM–CaCO3 
incorporation 
of gentamicin 
2.5% or 5% in 
powder
HA 0.45 Slight increase in 
setting time. Maximum 
strength unaffected. 
Extended release of 
gentamicin
71
  20% H2O ACP–DCPD HA 0.2 Increase in setting time. 
Decrease in mechanical 
properties
41
  0%–6% 2.5% Na2HPO4 α-TCP HA 0.6–0.87 Increase in setting time. 
Decrease in diametral 
tensile strength
72
  0%–1% 1% Na2HPO4 α-TCP, DCPD, 
CaCO3, and 
PHA
HA 0.35–0.40 Reduction injectability 14
  0%–1% Chondroitin 
sulfate and 
succinic acid
α-TCP–TTCP–
DCPD
HA 0.3 Increase in cohesion 
and antiwashout 
properties
73
  0%–2% 105 mM CaCl2 ACP–DCPD  
(α-BSM) 
HA 0.8 Support cell growth 
and osteogenesis
74
 Hyaluronate 0%–0.5% 0.5 M citric acid β-TCP–MCPM DCPD 0.4 Setting times were 
increased. Mechanical 
properties unaffected
75
  0%–8% 2.5% Na2HPO4 α-TCP HA 0.35 No effect on 
mechanical properties
76
  0%–1% 0.2 M PBS TTCP–DCPD HA 0.35 Increased injectability 77
 Cellulose 0%–2.2% Na2HPO4 TTCP–DCPA, 
α-TCP–CaCO3, 
DCPA–Ca(OH)2
HA 0.25 and 
0.27
Increase in setting time. 
Increase in mechanical 
properties
78,79
  0%–3% 0.2 M sodium 
phosphate
TTCP–DCPA, 
TTCP–DCPD
HA 0.5 Similar setting times 
to control. Mechanical 
properties increased. 
Increase in injectability
80
 Silk 0%–2% 0.9 NaCl 
solution
ACP–DCPD 
(α-BSM)
HA 0.8 Decrease in 
compressive strengths
74
  0%–2% 0.25 M 
NaHPO4/
Na2HPO4
α-TCP HA 0.4 Increase in flexural 
strength. No difference 
in setting time or cell 
viability respect to 
control
81
 Chondroitin   
 sulfate
0%–20% H2O and 0.5 M 
citric acid
ACP–DCPDa 
and β-TCP–
MCPMb
HAa and 
DCPDb
0.39–0.5 Slightly higher setting 
times and mechanical 
properties
41, 82
 Chitin 0%–4% H2O α-TCP–TTCP–
DCPD
HA 0.43 Reduction of setting 
times. Increase in 
compressive strength
83
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Polymer name % Weight/
specifications
Liquid  
phase
CPC  
composition
CPC  
end product
L/P  
ratio
Main effect References
 Albumen 0%–12% H2O or 
Na2HPO4 
solution
α-TCP HA 0.35 Macroporous self-
setting calcium 
phosphate foams 
are obtained. Faster 
resorption in vivo
21, 22
 Soybean- 
 derived   
 hydrogel
0%–20% Na2HPO4 
solution with or 
without gelatin
α-TCP HA 0.65 Injectable calcium 
phosphate foams with 
an enhanced osteoblast 
adhesion growth
24
Synthetic polymers
  Polyesters and  
 polyethers
0%–20% 2% Alginate in 
H2O
PCCP–DCPA HA 0.31–1 Scaffold immersed 
in PLGA solution. 
Increase in the 
mechanical properties 
in the presence of 
PLGA
84
  0%–3% PEG in H2O TTCP–DCPA HA 0.33 Concentrations 
higher than 1% 
decreased mechanical 
properties
85
  1.4% PPF N-vinyl 
pyrrolidone
TTCP–DCPA HA 0–1 Decrease in mechanical 
properties. Prolonged 
release of protein Rg1
86
  0%–1% Liquid 
(polysorbate 20)
Glycerol MCPM–β-TCP DCPD 0.21–0.44 Since the paste is 
formed with glycerol, 
no water is contained 
and reaction does no 
start until immersed 
in water. Setting times 
and compressive 
strength similar to 
control
87
  — PEG and 
glycerin
MCPM–β-TCP DCPD 0.27–0.4 Increased setting  
times. Higher cohesion 
and antiwashout 
properties. Higher 
inflammatory response 
than control
88
  0%–0.5% PEG 
and glycerin
Na2HPO4 and 
citric acid
ACP–DCPD HA 0.5 Decrease in setting 
times. Reduced 
injectability
89
  0%–10% 
Glycerol
Ca(OH)2, 
H3PO4, and H2O
α–TCP and 
TTCP
HA 0.43 Increase in setting 
time. Improvement 
of injectability and 
reduction in injecting 
force
90
 Polyacrylic   
  acid
0%–1.45% 0.0625 g/mL 
Gentamicin 
sulfate
MCPM–β-TCP DCPD 0.8 Controls the 
gentamicin release 
during prolonged time
91, 92
  0%–20% 
Acrylamide
0.5% MBAM, 
0.25% 0.30 mL/g 
TEMED, 2.5% 
Na2HPO4, and 
1% PA
α-TCP HA 0.30–0.32 Significant increase 
in the compressive 
and tensile strength. 
Reduction of the 
porosity
93
Table 2. (Continued)Perez et al.  9
Polymer name % Weight/
specifications
Liquid  
phase
CPC  
composition
CPC  
end product
L/P  
ratio
Main effect References
  35% Polymethyl-
vinyl ether-
maleic acid or 
10% polyacrylic 
acid
H2O TTCP–DCPD–
TCP
HA 0.25 Considerable increase 
in compressive 
strength, even at short 
times. Lower cell 
viability than control 
after 24 h. After 1 
week, similar cell 
viability to control
94
  Fibrin glue — Fibrin glue 
(Hualan 
Biological 
Engineering, 
China)
TTCP–DCPA HA 0.2–1 Increase in setting 
times. Considerable 
increase in 
compressive strength. 
No  
effect on cell 
proliferation and 
differentiation after 
14-day culture
95
Solid phase
  Natural polymers
  Gelatin MS 0%–10%; MS 
size 15.48–8.64 
µm; bFGF, TGF-
β1 and BMP2 
incorporated
1% Na2HPO4 α–TCP–DCPA–
CaCO3
HA 0.91 Setting time and 
macroporosity 
were increased. 
Compression strength 
was decreased. 
Prolonged release of 
growth factors was 
obtained
96–98
  Gelatin MS 10%; 50–150 
µm. Gentamicin 
incorporated in 
MS (900 mg)
1% Na2HPO4 α–TCP–
MCPM–CaCO3
HA 0.4 Incorporation of MS 
increased setting 
times and porosity. 
Compressive strength 
was decreased, but 
could be enhanced by 
the incorporation of 
calcium sulfate hydrate. 
Release of gentamicin 
can be controlled 
depending on cross-
link of MS
99
  Gelatin MS 5%; 20 µg 
of BMP2 
incorporated in 
implant
1 M Na2HPO4 TTCP–DCPA HA 0.45 Release of BMP2 is 
more prolonged when 
BMP2 is incorporated 
in gelatin MS. Can 
accelerate healing 
osteoporosis in vivo
100
  Gelatin MS 0%–5% 1 M Na2HPO4 TTCP–DCPA HA 0.4 The mechanical 
properties of 
composite initially 
increased but 
decrease with 
degradation. Increased 
macroporosity. 
Optimum amount 
is 2.5% of mass 
fraction MS. Good 
biocompatibility in 
vitro and in vivo
101
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Polymer name % Weight/
specifications
Liquid  
phase
CPC  
composition
CPC  
end product
L/P  
ratio
Main effect References
  Gelatin MS 48%–57%; size 
37 ± 31 µm
2% Na2HPO4 α–TCP–DCPA HA 0.35 Adequate degradation 
in vivo. Increased 
macroporosity
102
 Collagen 0%–5% H2O/0.2 
M neutral 
phosphate
TTCP–DCPA HA 0.29 Prolonged setting 
times and reduced 
mechanical properties
47
 Chitosan 0%–2% H2O ACP–DCPD HA 0.5 Setting times 
reduced. No effect on 
compressive strength
103
 Cellulose 0%–6.4% 2.5% NaHPO4 α-TCP HA 0.6–0.87 Increase in injectability 104
 Alginate   
 microbeads
1.2% sodium 
alginate; 0%–70% 
microbeads; size 
207 µm
15% Chitosan in 
H2O
TTCP–DCPA HA 0.25 Decrease in flexural 
strength. Cells were 
able to survive, 
proliferate, and 
differentiate
105–108
 Alginate 0%–1% H2O ACP–DCPD HA 0.5 Setting times 
decreased. 
Compressive strength 
decreased as polymer 
concentration 
increased. Injectability 
reduced
103
Synthetic polymers
 PLGA   
 microspheres
20%; 
Microspheres 
10–110 µm 
diameter
2% Na2HPO4 
BMP2 
adsorbed and 
entrapped on 
microparticles
α-TCP, DCPA, 
and CaCO3
HA 0.35–0.5 Controlled degradation 
of PLGA allows for a 
prolonged release of 
the BMP2. In vitro and 
in vivo were shown 
to be biocompatible 
and the presence of 
the microparticles 
allowed to obtain 
interconnected 
porosity for tissue 
ingrowth
26, 
109–114
  PLGA MS 5%; MS size 7–14 
µm; gentamicin 
or BMP2 loading
H2O or 4% 
Na2HPO4
TTCP–DCPA HA 0.3 Controlled and 
prolonged release 
of growth factor. 
No change of the 
setting times or 
the mechanical 
performance
115, 116
  PGA fibers 0%–45%; fraction 
volume fiber 
length 8 mm
15% Chitosan 
solution or H2O
TTCP–DCPA or 
TTCP–DCPD
HA 0.22–0.4 Material exceeded 
strength of cancellous 
bone. Increased 
flexural strength. Cells 
presented excellent 
viability, differentiated, 
and synthesized bone 
minerals
117–120
  PCL and PLLA  
 fibers
0%–7%; fibers 
3 mm
1% Na2HPO4 α-TCP, DCPA, 
and CaCO3
HA 0.33 Connective channel-
like porous structure 
was created in the 
CPC. Toughness was 
improved. Decreased 
flexural strength
121
Table 2. (Continued)Perez et al.  11
Polymer name % Weight/
specifications
Liquid  
phase
CPC  
composition
CPC  
end product
L/P  
ratio
Main effect References
  PGA fibers 0%–24%; 
diameter 
0.30–0.349 mm
3.5 M H3PO4 + 
100 mM sodium 
citrate
β-TCP (Plasma 
Biotal, UK)
DCPD 0.67 The yield and ultimate 
strength increased. 
Modulus of elasticity 
also increased in 
flexural testing. Regular 
fiber orientation led  
to higher  
mechanical properties 
compared to random 
fibers
122
  Aramide fibers 0%–9.5%; 
fraction volume 
fiber length 
3–200 mm
H2O TTCP–DCPA HA 0.33 Ultimate strength 
significantly increased. 
The longer the 
fibers, the higher the 
mechanical properties
123
 Polyamide   
 fibers
0%–1.6%; 
diameter 0.1 
mm and length 
3 mm
2.5% NaHPO4 α-TCP HA 0.55 Increase in 
compression 
strength, but was 
not concentration 
dependent
124
 Polyacrylic   
 acid
0%–25%; 45- to 
75-µm particles
H2O TTCP–DCPA HA 0.4 Increase in setting 
time proportional 
to increase in 
concentration. 
Significant increase 
in the compressive 
strength
125
CPC: calcium phosphate cement; L/P: liquid to powder; TCP: tricalcium phosphate; HA: hydroxyapatite; PBS: phosphate buffered saline; MCPM: mono-
calcium phosphate monohydrate; DCPD: dicalcium phosphate dehydrate; ECM: extracellular matrix; ACP: amorphous calcium phosphate; TTCP: tetra-
calcium phosphate; DCPA: dicalciumphoshphate anhydrous; ALP: alkaline phosphatase; PHA: precipitated hydroxylapatite; PCCP: partially crystallized 
calcium phosphate; PLGA: poly(lactic-co-glycolic acid); PEG: polyethylene glycol; PPF: poly(propylene fumarate); MBAM: N,N′-methylenebisacrylamide; 
TEMED: N,N,N′N′-tetramethylethylenediamide; PA: polyacrylate; MS: microsphere; TGF: transforming growth factor; BMP2: bone morphogenetic pro-
tein 2; PGA: polyglycolide acid; PCL: poly(ε-caprolactone); PLLA: poly(l-lactic acid); bFGF: basic fibroblast growth factor. 
concentrations. Actually, optimum mechanical properties 
were obtained with a 2 wt.% gelatin solution incorporated 
into a CPC composed of MCPM–CaCO3.40 CPCs (both 
ACP–DCPD and MCPM–CaCO3 cements) with gelatin 
concentrations of 10–20 wt.% clearly showed diminished 
compressive strength.38,41 In contrast, 5 wt.% gelatin was 
optimum for a α-TCP CPC.44 Another study showed no dif-
ference due to the presence of gelatin in the CPC.128
Gelatin was also used as foaming agent in CPC. Self-
setting gelatin–α-TCP foams are obtained by mixing α-TCP 
with a foamed gelatin solution, which after setting results in 
a HA solid foam, with high macroporosity and adequate 
cohesion and injectability.23,25
Collagen.  Collagen is a triple helical structure protein 
and is the most abundant protein found in bone. Colla-
gen is insoluble in water and requires acidic conditions to 
solubilize. The presence of collagen has a similar effect to 
that of gelatin in some cases, which is probably expected, 
as gelatin is denaturized collagen. Nevertheless, as colla-
gen has a triple helical structure, the RGD sequence is not 
exposed. Instead, other amino acid sequences are exposed 
such as the glycine–phenylalanine–glutamine–glycine–
glutamic acid–arginine sequence, which may also enhance 
cell adhesion. The effect of adding collagen on the in vitro 
biological properties of tetracalcium phosphate (TTCP)–
dicalciumphoshphate anhydrous (DCPA), MCPM–β-TCP 
and α-TCP CPCs was assessed in a cell culture study.45,46,129 
Initial adhesion was enhanced when the CPC was combined 
with collagen45,46 and so was the proliferation.129
Collagen also influenced other CPC properties. When 
the collagen is incorporated during the liquid phase, the set-
ting times are in the range needed for orthopedic applica-
tions, although setting times increase as collagen 
concentration increases.47
Adding collagen decreases the mechanical properties of 
a TTCP–DCPA CPC, and this decrease is more significant 
with increasing collagen concentrations.45,47 In contrast, the 12  Journal of Tissue Engineering 3(1)
mechanical properties are slightly improved when collagen 
is incorporated into a brushite CPC.46
Chitosan.  Chitosan is a linear polysaccharide composed 
of randomly distributed D-glucosamine and N-acetyl-
D-glucosamine units. Chitosan can clot blood and has 
antibacterial properties. Chitosan is insoluble in water and 
soluble under acidic conditions. When incorporated into 
different CPCs composed of ACP–DCPD, α–TCP, TTCP, 
MCPM–CaCO3, or DCPD–Ca(OH)2, chitosan increases 
setting time and inhibits the setting reaction.41,48–51 Nev-
ertheless, chitosan significantly reduces setting times for 
TTCP–DCPA cements.52,130
The effect of chitosan on flexural and compressive 
strength has been widely studied. Chitosan increases the 
flexural strength of a chitosan–CPC composite composed of 
TTCP–DCPA considerably, and the highest value was 
reached when 15–20 wt.% chitosan was incorporated into 
the CPC,48,53,54,59,61,117 although optimum results also 
occurred when CPC–chitosan is synergistically combined 
with Vicryl fibers or alginate microbeads.105,117 Another 
approach, which actually does not incorporate the polymer in 
the liquid phase or in the powder phase but in the CPC paste, 
being the only report that has shown such methodology, also 
reported an increase in the flexural strength of the compos-
ite.131 Even though this last work does not correspond to any 
of the two sections (polymers incorporated into the liquid 
phase or in the powder phase), it was incorporated into this 
section since it is the only case reported and because it shows 
similar trend to the works in which chitosan was incorpo-
rated into the liquid phase. In general, flexural strength 
decreases when the amount of chitosan increases >20 
wt.%.52,55,56 Similarly, compressive strength drastically 
decreases when chitosan increases to >10 wt.%.41,50 
Nevertheless, the compressive strength of CPC composites 
containing chitosan generally increases.50,62 An interesting 
property of chitosan is its ability to increase the antiwashout 
resistance of CPC63–67 but not injectability.63–67
Adding chitosan has a moderate effect on the cell 
response to CPC. No cytotoxicity38,49,55–58,62,131 is found in 
chitosan-containing CPCs. Moreover, ALP activity 
increases considerably in the presence of chitosan when 
mesenchymal stem cells are cultured on a TTCP–DCPA 
CPC composite containing 15 wt.% chitosan.59,60 The same 
authors reported a similar ALP value for the same chitosan–
CPC composite compared to the control CPC when cultur-
ing MC3T3-E1 cells.53 Cells also survive when encapsulated 
in sodium alginate droplets and combined with a CPC paste 
containing chitosan.57,132 When preosteoclastic cells are 
cultured on a CPC containing chitosan, cell morphology 
and tartrate-resistant acid phosphatase (TRAP) activity are 
similar to a control CPC, although the osteoclasts are 
larger.56,133
Two different chitosan-containing CPCs composed of 
either MCPM–CaO or DCPD–Ca(OH)2 have shown a 
lower biodegradation in the presence of chitosan.68 The 
effect of chitosan on the protein release properties of a CPC 
loaded with protein A has also been studied. Incorporating 
chitosan results in sustained release when both the amount 
of chitosan incorporated and the L/P ratio of the composite 
are adjusted.69
Alginate.  Alginate is an anionic polysaccharide found 
in brown algae cell walls. It is capable of absorbing 200–
300 times its own weight in water and creating a viscous 
gum. It is known as a biocompatible material, and one of its 
main features is that it gels through chelation with divalent 
cations. Alginate has been used for cell immobilization or 
encapsulation.
When DCPA–TTCP is used as the CPC powder phase, 
incorporating sodium alginate clearly increases the setting 
times, and this increase is dose dependent.70 Similar results 
are found for CPCs composed of MCPM–CaCO3 combined 
with alginate.71 Nevertheless, this increase in the setting times 
was only observed when the amount of sodium alginate was 
>2 wt.%.12 A CPC composed of ACP–DCPD also showed 
increased setting time in the presence of sodium alginate.41
The compressive strength of a CPC composed of 
DCPD–ACP containing sodium alginate decreases as the 
concentration of polymer increases.103 This was also 
observed for TTCP–DCPA and α-TCP cements, in which 
the incorporation of low amounts of sodium alginate 
decreases diametral tensile strength.12,72 Nevertheless, dia-
metral tensile strength is not affected by incorporating 
sodium alginate at up to 10 wt.% into TTCP–DCPA 
cement.70 Accordingly, another study reported a decrease in 
mechanical properties when the amount of alginate incor-
porated is 20 wt.%.41
Similar to chitosan, sodium alginate hinders the CPC 
setting reaction and, therefore, delays HA formation. A 
reduction of injectability has also been reported for sodium 
alginate-containing cements.14,103 Nevertheless, the pres-
ence of sodium alginate generally increases the antiwash-
out properties of the CPC and their cohesion.73
Sodium alginate has little effect on cell proliferation and 
differentiation of human bone marrow-derived mesenchy-
mal stem cells.74
Hyaluronate.  Hyaluronate is an anionic nonsulfated 
glycosaminoglycan that is biocompatible and may be 
cross-linked to produce hydrogels. The molecular weight 
of the polymer is very important when combining hyalu-
ronate with CPC. The setting times of a CPC composed 
of β-TCP–MCPM increase with increasing hyaluronate 
concentration dissolved in the liquid phase, as long as the 
molecular weight is low (300 and 750 kDa), whereas the 
values are unaffected in the presence of higher molecular 
weight hyaluronate (1640 kDa).75
Hyaluronate incorporated into a α-TCP CPC does not 
significantly affect the mechanical properties of the Perez et al.  13
composite.75,76 In contrast, sodium hyaluronate has high 
viscosity and creates a network with Ca2+ when incorpo-
rated into the CPC liquid phase, which increases injectabil-
ity of the paste.77
Adding hyaluronic acid slightly delays new bone forma-
tion in vivo, although the response is dependent on the ini-
tial composition of the CPC solid phase.134
Cellulose.  Cellulose is a polysaccharide of several hun-
dreds of β(1→4) linked d-glucose units. Cellulose is found 
in the cell walls of green plants and algae. Variations in the 
monomers may change the structure of cellulose, hydroxy-
lation forms hydropropyl methylcellulose (HPMC), and the 
substitutions with carboxyl groups form carboxy methyl-
cellulose (CMC).
Adding HPMC (0–4 wt.%) to a CPC generally increases 
setting time78,79 of α-TCP–CaCO3, DCPA–Ca(OH)2, and 
TTCP–DCPA. Nevertheless, values similar to control CPC 
values have been reported80 in the compositions of TTCP–
DCPA and TTCP–DCPD cements when HPMC was incor-
porated (0–3 wt.%).80
The mechanical properties (e.g. diametral tensile 
strength, compressive strength, and elastic modulus) for 
different CPCs composed of α-TCP–CaCO3, DCPA–
Ca(OH)2, TTCP–DCPA, and TTCP–DCPD tend to increase 
as the amount of HPMC increases.78–80 Nevertheless, oppo-
site results have also been reported, in which the modulus 
was reduced with added HPMC in a CPC composed of 
ACP–DCPD.73 HPMC drastically increases the injectabil-
ity of the CPC even at low concentrations, and the injecta-
bility tends to increase as polymer concentration is 
increased for TTCP–DCPA, TTCP–DCPD, and α-TCP 
compositions.80
Adding CMC to the CPC does not significantly improve 
the in vitro biological properties such as cell proliferation 
or differentiation.74 HPMC has also been used for drug 
delivery applications. The amount of gentamicin released 
from a CPC composite made of β-TCP–MCPM and HPMC 
is reduced, probably due to chemical binding between the 
polymer and the antibiotic.91
Others.  Other natural polymers have also been com-
bined with CPCs, but only a few studies have been reported. 
For example, silk reduces maximum compressive strength 
and the elastic modulus compared to those in a control 
CPC.74 Nevertheless, flexural strength increases signifi-
cantly in the presence of silk (0.5, 1, and 2 wt.%).81 Setting 
times do not vary in the presence of silk fibroin.81 Silk can 
also be used to increase CPC cohesion.135 No differences in 
terms of cell viability compared to the control CPC were 
observed when silk was incorporated.81 Another example 
is incorporating starch and chondroitin sulfate into a CPC, 
which results in slightly higher setting times and mechani-
cal properties compared to those of a control CPC.41,82,103 
Albumen and soybean have also been incorporated into 
CPCs, with the purpose of creating a liquid phase foam, 
which enables the production of a macroporous injectable 
CPC.22,24
Finally, chitin has been incorporated into a CPC com-
posed of α-TCP–TTCP–DCPD at 4 wt.% chitin, resulting 
in reduced setting times from 32 min in the control to 14 
min for the composite CPC.83 Incorporating chitin also 
increases compressive strength from 23 MPa in the control 
to 33 MPa in the composite material.83 However, a high 
chitin content is detrimental to CPC resorption under in 
vivo conditions.136
Synthetic polymers
Polyesters and polyethers.  Polyesters are thermoplastic 
polymers that contain an ester functional group in their 
main chain. They are degradable, and the degradation 
rate is highly dependent on composition. Although hydro-
lytically degradable, they have far lower water absorp-
tion and shrinkage than those of natural polymers. While 
poly(ε-caprolactone) is highly flexible, polylactide acid 
(PLA) and polyglycolide acid (PGA) have relatively high 
strength and elastic modulus. Therefore, one of the possi-
ble main functions of the polyesters in CPCs is to increase 
mechanical strength. However, these polymers are not 
water soluble, and therefore, they cannot be directly incor-
porated into the liquid phase of the CPC. With this in mind, 
poly(lactic-co-glycolic acid) (PLGA) dissolved in dichlo-
romethane was infiltrated into the macropores of a alginate/
CPC scaffold. Incorporating PLGA in CPC at a concentra-
tion of 20 wt.% increased significantly the mechanical 
strength.84 Opposite results were observed when water-sol-
uble copolymers were obtained by combining polyethylene 
glycol (PEG) with poly(γ-benzyl l-glutamate), poly(γ-
ethyl  l-glutamate), and poly(γ-methyl l-glutamate) and 
incorporated into a CPC. As a result, mechanical strength 
decreased when polymer concentration was >1 wt.%.85 
The incorporation of poly(propylene fumarate) (PPF) also 
decreases the mechanical strength of a CPC as the amount 
of PPF is increased in the composite.86 The combination 
of a CPC composed of TTCP–DCPA with PPF resulted in 
prolonged release of protein Rg1 with complete release 
over 20 days without regard to the protein content incor-
porated.86
PEG is a polyether composed of glycerol monomers. It 
has been used to obtain premixed CPCs. In fact, when the 
monomers are combined with CPC, water-free pastes are 
formed, which can be stored for a long period without 
reacting. This means that CPC pastes can be prepared at the 
bench and stored until needed (e.g. operating 
theater).49,78,87,137 When the premixed CPC pastes are 
immersed in water for the reaction, they present setting 
times and compressive strength similar to the conventional 
CPC.87 However, the mechanical strength decreases in the 
presence of PEG after a 7-day reaction in water,88 and the 14  Journal of Tissue Engineering 3(1)
injectability of the CPC pastes is reduced with added PEG, 
glycerol, and glycerin.89,90 Contradictory results were found 
for setting times; the presence of glycerin and PEG 
decreases the setting times of ACP–DCPD cement.89 
Although PEG increases the setting times of β-TCP–
MCPM CPC,88 it is known as an effective antiwashout 
agent.88
Polyacrylic acid.  Polyacrylic acid (PAA) and its deriva-
tives are capable of absorbing water many times their 
weight. At neutral pH, PAA loses protons and is then nega-
tively charged, facilitating the combination with a range 
of antibiotics or similar drugs for sustained release. When 
gentamicin sulfate is incorporated into CPC modified with 
PAAs, the antibiotic shows quite sustained release from 
the cement composite.92 The final amount of released gen-
tamicin was thus reduced in the PAA–CPC composites.91 
Nevertheless, one of the main problems is that the reaction 
is hindered, as few reactions occur in the presence of PAA 
even after 1 month.128
Polyacrylates have considerable effects on mechanical 
properties. Compressive strength increases substantially to 
55 MPa when ammonium PAA is incorporated into the 
CPC, which is contrasted with 25 MPa for a CPC without 
PAA.93 The increase in compressive strength can also be 
deduced from the reduction in composite porosity.93 
Furthermore, adding PAA allowed the brittle CPC to 
become more ductile.138 Within the same family of poly-
mers, a 35 wt.% aqueous solution of poly(methyl vinyl 
ether-maleic acid) and 10 wt.% PAA were added to a CPC 
powder composed of 60 wt.% TTCP, 30 wt.% DCPD, and 
10 wt.% TCP. As a result, mechanical properties increased 
considerably with respect to the control CPC, reaching ~70 
MPa after 2 weeks compared to ~18 MPa in the control 
CPC. Moreover, 70 MPa is achieved in as short as 30 min 
in a CPC containing 10 wt.% PAA.94 TTCP–DCPA CPC 
also shows a significant increase in strength (diametral ten-
sile strength and compressive strength) with added 
poly(methyl vinyl ether-maleic acid).139
Incorporating PAA and poly(methyl vinyl ether-maleic 
acid) results in lower cell viability than that in a control 
CPC composed of TTCP–DCPD–TCP after the initial 24 h; 
however, cell viability recovered to a level higher than that 
of the control CPC after 1 week.94 In general, lower cyto-
toxicity is achieved when CPCs are combined with PAA 
and derivatives compared to the acrylic bone cements.140 
Composite CPCs have proven in vivo tissue compatibility, 
suggesting possible clinical applications.141
Fibrin glue.  Fibrin glue is produced as a reaction prod-
uct of fibrinogen with thrombin and is used to create a 
fibrin clot. Fibrin glue significantly increases setting times 
of a CPC composed of TTCP–DCPA powder.95 The pres-
ence of fibrin glue also increases compressive strength 
significantly.95 Nevertheless, incorporating fibrin glue into 
TTCP–DCPA cement does not have a significant effect on 
the cell proliferation or ALP activity after 14 days of cul-
ture.95 Furthermore, no significant difference in bone for-
mation is observed due to the incorporation of fibrin glue.142
Polymer addition as a solid phase
The addition of polymers in solid state, as a second phase in 
the CPCs, is aimed at achieving two main objectives. On 
one side, to act as a reinforcing phase that enhances the 
mechanical properties of the CPC and on the other side to 
create macroporosity in the CPC after dissolving the poly-
mer, which promotes tissue colonization and eventually 
enhances CPC resorption. Polymers can be added in the 
form of powders, MSs, or fibers.
Natural polymers.  Adding natural polymers in the form of 
a liquid phase is preferred, as explained in the previous sec-
tion, because they dissolve well in water-based liquid. 
However, the solid forms of natural polymers, such as MS, 
fibers, and powders, have also been studied. Gelatin MSs 
have been incorporated into CPC powder to stimulate the 
degradation and resorption of a CPC.96–102,109 Different 
amounts and sizes of gelatin MSs were added to the powder 
phase of the CPC, which was then mixed with the liquid 
phase. As a result, the MSs degraded in water with time to 
provide space for cells to penetrate and for new bone 
ingrowth. Growth factors can be loaded for therapeutic 
applications.98,100
Lyophilized collagen has also been incorporated as the 
solid phase. However, this results in significant difficulty in 
mixing and retards the setting reaction.47 Chitosan has also 
been incorporated into the solid phase of a ACP–DCPD 
cement, and setting times are reduced, but no effect on 
compressive strength was observed.103 The injectability of 
an α-TCP cement was increased when cellulose was incor-
porated into the powder phase of the cement.104
Alginate has been added to a CPC (TTCP–DCPA) in the 
form of microbeads,54 resulting in an increase in the 
mechanical properties. Moreover, the presence of alginate 
microbeads helped the formation of macrochannels in the 
CPC, which stimulate vascularization in vivo and help bio-
degradation of material.143 In contrast, if alginate is added 
as smaller particles as the powder phase, setting times 
decrease, and the compressive strength and injectability 
also decrease.103
Because of the specific property of sodium alginate for 
encapsulating tissue cells within gelled microcap-
sules,54,106–108 cell-encapsulating alginate beads have also 
been added to CPCs. Cells inside the alginate beads are via-
ble and undergo appropriate cellular processes, such as cell 
mitosis and tissue differentiation. Therefore, a combined sys-
tem composed of CPC–alginate with cells is considered a 
possible tissue-engineered construct. However, concerns 
may remain as to the mechanical properties of the CPC.Perez et al.  15
Synthetic polymers.  Compared to natural polymers, the 
synthetic polymers are added more preferably in the form 
of a solid phase, which is mainly due to the difficulty in 
dissolving synthetic polymers in water-based liquids. The 
well-known degradable copolymer PLGA has been widely 
used as a second solid phase of CPCs to deliver growth 
factors and antibiotics in a sustained and controllable 
manner.110,111,115,116 However, even though the growth fac-
tor is released from the polymer, this can also be adsorbed 
on the surface of the CPC due to its high affinity for pro-
teins, this resulting in a reduction of the final release 
rate.144 As these degradable biopolymers added to CPCs 
have already proven to be biocompatible,112 more atten-
tion has been given to the control of degradation rate and 
obtaining highly interconnected macroporosity.26,109,113,114
The fiber form of synthetic polymers has been incorpo-
rated most widely because of the beneficial mechanical 
properties of the fibers, such as tensile strength and elastic 
modulus.30,105,117,118 In general, when polyester fibers were 
incorporated, the flexural strength and work of fracture 
increased considerably, and the behaviors were greatly 
dependent on the fiber length and diameter.27,105,119–122,145 
Of special interest is the incorporation of aramide fibers, 
which have extremely high flexural strength and work of 
fracture compared to any other types of polymers, includ-
ing PGA.123,146 In contrast, adding polyamides such as 
nylon has no significant effect on the mechanical properties 
of α-TCP cement.124 It was also shown that electrospun 
submicron fibers enhanced mineralization behavior of cells 
cultured on the CPCs, which was attributed to the higher 
surface area and some possible biomimetic features of the 
fiber morphology.121 The fiber form of degradable poly-
mers also generates pores during degradation within the 
cement.147 Acrylate derivatives incorporated into CPC also 
showed increased setting time, and the increase was pro-
portional to the polymer concentration.125 The compressive 
strength was also considerably increased.125
Conclusion
The combination of polymers with CPC, either solubilized 
in the liquid phase or as a second solid phase, has proven to 
be an interesting strategy for the development of bone sub-
stitutes with improved performance. Whereas CPCs have 
outstanding biocompatibility and osteoconductivity, they 
also have some intrinsic limitations that can be counter-
acted by the incorporation of a polymer in their formula-
tion. The range of properties that can be modified by the 
addition of a polymer is broad, covering aspects as diverse 
as the rheological or the mechanical behavior, the rate of 
resorption, or the cell and tissue response. The large num-
ber of publications on this subject demonstrates, from dif-
ferent perspectives, the feasibility of this approach. 
However, there are still many areas for further work, 
especially in terms of understanding and controlling the 
interactions between the organic and inorganic phases, 
which may open new avenues for the development of novel 
self-assembled materials through biomimetic routes. 
Furthermore, the biological behavior of the CPCs can still 
be further improved and in this sense, incorporation of 
other molecules, such as growth factors or genes, can over-
come some of the limited biological functionalities. 
Therefore, the incorporation of these different types of pol-
ymers may be a useful tool to be able to control the delivery 
of the different biologically active molecules.
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